Form 4 Filing for Amylyx Pharmaceuticals, Inc. - Paul R. Fonteyne

This filing details a Form 4 submission for Paul R. Fonteyne, a director at Amylyx Pharmaceuticals, Inc. (AMLX). On June 4, 2026, Mr. Fonteyne was granted a stock option to acquire 24,372 shares of common stock at an exercise price of $0.00 per share. The option vests in full on the earlier of June 4, 2027, or the next annual meeting, contingent upon his continued service. The underlying transaction involved 24,372 shares of common stock, and post-transaction, Mr. Fonteyne holds 24,372 shares. The filing was signed on June 8, 2026, by Joshua B. Cohen as Attorney in Fact.